FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W23465562> ?p ?o ?g. }

• W23465562 endingPage "1257" @default.
• W23465562 startingPage "1248" @default.
• W23465562 abstract "A number of drugs currently being tested in clinical trials as possible angiogenesis inhibitors were not originally developed with the intention of suppressing tumour angiogenesis. Thalidomide and interferon alpha are obvious examples of such drugs. This list of 'accidental' angiogenesis inhibitors may include established agents such as conventional cytotoxic chemotherapeutic drugs as well as the new generation of anticancer drugs known as anti-oncoprotein signal transduction inhibitors. With respect to the former, the potential of such drugs to inhibit angiogenesis could be the result of their ability to cause collateral damaging effects on cycling endothelial cells found in newly formed blood vessels, or inhibiting other vital endothelial cell functions necessary for angiogenesis. The antitumour vascular side-effects of chemotherapy may be optimised by administering such drugs continuously on a more frequent (e.g. weekly or even daily) basis at levels well below the maximum tolerated dose (MTD), especially when this is done in combination with newly developed anti-angiogenic drugs such as vascular endothelial cell growth factor (VEGF) receptor blocking antibodies. This strategy may minimise or delay the problems of host toxicity and acquired drug resistance. The possibility of anti-angiogenic effects mediated by signal transduction inhibitors such as ras farnesyltransferase inhibitors (ras FTI's), or drugs which block receptor tyrosine kinases (e.g. ErbB2/neu) such as Herceptin, may be the consequence of such oncogenes inducing or upregulating various pro-angiogenic molecules such as VEGF (vascular endothelial cell growth factor) in tumour cells. Hence, treatment of tumour cells with such drugs can lead to downregulation of tumour cell-associated VEGF expression and this can contribute to an anti-angiogenic effect of the drug in vivo. In addition, some of these drugs may also affect certain 'activated' endothelial cell functions directly so as to block angiogenesis. An awareness of the potential of such conventional or experimental anticancer drugs to affect tumour growth through blockade or suppression of angiogenesis has implications for how anticancer drugs may be used clinically, either alone, or in combination with other drugs to optimally treat cancer." @default.
• W23465562 created "2016-06-24" @default.
• W23465562 creator A5010799165 @default.
• W23465562 creator A5018738783 @default.
• W23465562 creator A5033748917 @default.
• W23465562 creator A5035228727 @default.
• W23465562 date "2000-06-01" @default.
• W23465562 modified "2023-09-26" @default.
• W23465562 title "‘Accidental’ anti-angiogenic drugs" @default.
• W23465562 cites W103592546 @default.
• W23465562 cites W139545237 @default.
• W23465562 cites W1483388049 @default.
• W23465562 cites W1515556443 @default.
• W23465562 cites W1554763487 @default.
• W23465562 cites W156576096 @default.
• W23465562 cites W1579297325 @default.
• W23465562 cites W1604140953 @default.
• W23465562 cites W1607187127 @default.
• W23465562 cites W1658047882 @default.
• W23465562 cites W1762724222 @default.
• W23465562 cites W177380973 @default.
• W23465562 cites W1877527541 @default.
• W23465562 cites W1920828316 @default.
• W23465562 cites W1965181694 @default.
• W23465562 cites W1965995529 @default.
• W23465562 cites W1976570855 @default.
• W23465562 cites W1978165300 @default.
• W23465562 cites W1979307478 @default.
• W23465562 cites W1985804036 @default.
• W23465562 cites W1988307856 @default.
• W23465562 cites W1992177486 @default.
• W23465562 cites W1993011693 @default.
• W23465562 cites W1993362999 @default.
• W23465562 cites W1994014733 @default.
• W23465562 cites W1995028613 @default.
• W23465562 cites W1997471955 @default.
• W23465562 cites W2000688337 @default.
• W23465562 cites W2001258296 @default.
• W23465562 cites W2001595119 @default.
• W23465562 cites W2004239325 @default.
• W23465562 cites W2013312964 @default.
• W23465562 cites W2014356708 @default.
• W23465562 cites W2015344488 @default.
• W23465562 cites W2019273955 @default.
• W23465562 cites W2020004435 @default.
• W23465562 cites W2021326683 @default.
• W23465562 cites W2022082662 @default.
• W23465562 cites W2029883816 @default.
• W23465562 cites W2033791403 @default.
• W23465562 cites W2036082581 @default.
• W23465562 cites W2037141117 @default.
• W23465562 cites W2037480365 @default.
• W23465562 cites W2041356743 @default.
• W23465562 cites W2048428832 @default.
• W23465562 cites W2054979979 @default.
• W23465562 cites W2058591356 @default.
• W23465562 cites W2063176993 @default.
• W23465562 cites W2064739543 @default.
• W23465562 cites W2067055586 @default.
• W23465562 cites W2067121396 @default.
• W23465562 cites W2068391687 @default.
• W23465562 cites W2070108397 @default.
• W23465562 cites W2072335004 @default.
• W23465562 cites W2077391174 @default.
• W23465562 cites W2081697027 @default.
• W23465562 cites W2086637561 @default.
• W23465562 cites W2086880360 @default.
• W23465562 cites W2093915058 @default.
• W23465562 cites W2094699429 @default.
• W23465562 cites W2100272171 @default.
• W23465562 cites W2106691610 @default.
• W23465562 cites W2109327605 @default.
• W23465562 cites W2112811825 @default.
• W23465562 cites W2124891058 @default.
• W23465562 cites W2125505202 @default.
• W23465562 cites W2133138712 @default.
• W23465562 cites W2134384575 @default.
• W23465562 cites W2139360111 @default.
• W23465562 cites W2142918195 @default.
• W23465562 cites W2146651717 @default.
• W23465562 cites W2150048971 @default.
• W23465562 cites W2167455663 @default.
• W23465562 cites W2340893063 @default.
• W23465562 cites W4255042798 @default.
• W23465562 doi "https://doi.org/10.1016/s0959-8049(00)00092-7" @default.
• W23465562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10882863" @default.
• W23465562 hasPublicationYear "2000" @default.
• W23465562 type Work @default.
• W23465562 sameAs 23465562 @default.
• W23465562 citedByCount "174" @default.
• W23465562 countsByYear W234655622012 @default.
• W23465562 countsByYear W234655622013 @default.
• W23465562 countsByYear W234655622014 @default.
• W23465562 countsByYear W234655622015 @default.
• W23465562 countsByYear W234655622016 @default.
• W23465562 countsByYear W234655622017 @default.
• W23465562 countsByYear W234655622018 @default.
• W23465562 countsByYear W234655622019 @default.

• next